Given that previous studies showed that breast cancer, as well as leukemic cells, is sensitive to dual CK2/PIM-1 inhibitor treatment [35,36,37], two leukemic cell lines, i.e., CCRF-CEM and K-562, and breast cancer cells, i.e., MCF-7, were used in the present study. This evidence concerns the gene PIM1 and breast carcinoma.